SCHEMBL2769382

SCHEMBL2769382

CC(C)C(CO)NC(=O)c1cccc2c1CCc1cccc3[nH]nc-2c13

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.44
RAB9A P51151 2/20 0.44
MAPK8 P45983 2/20 0.40
MAPK9 P45984 2/20 0.40
MAPK10 P53779 2/20 0.40
ABL1 P00519 7/20 0.36
BCR P11274 7/20 0.36
KDM4E B2RXH2 3/20 0.36
MEN1 O00255 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDR P35968 2/20 0.36
KMT2A Q03164 2/20 0.36
CDC7 O00311 1/20 0.36
PLK4 O00444 1/20 0.36
CHEK1 O14757 1/20 0.36
IKBKB O14920 1/20 0.36
RGS12 O14924 1/20 0.36
AURKA O14965 1/20 0.36
GAK O14976 1/20 0.36
PDPK1 O15530 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2769753 0.87 NPC1 (0.51) NPC1RAB9AMAPK8MAPK9MAPK10
SCHEMBL2769418 0.79 ABL1 (0.46) NPC1RAB9AMAPK8MAPK9MAPK10
SCHEMBL2768161 0.77 KDR (0.50) NPC1RAB9AMAPK8MAPK9MAPK10
SCHEMBL2768004 0.77 MAPK8 (0.52) NPC1RAB9AMAPK8MAPK9MAPK10
SCHEMBL2768451 0.74 NPSR1 (0.47) MAPK8KDM4EMEN1ALDH1A1KMT2A
SCHEMBL2768810 0.73 KMT2A (0.50) MAPK10MEN1ALDH1A1KMT2AROCK2
SCHEMBL2768700 0.73 MAPK10 (0.52) NPC1RAB9AMAPK8MAPK9MAPK10
SCHEMBL2771305 0.70 MAPK8 (0.57) NPC1RAB9AMAPK8MAPK9MAPK10
SCHEMBL2768727 0.68 MAPK8 (0.52) NPC1RAB9AMAPK8MAPK9MAPK10
SCHEMBL2771632 0.68 MAPK8 (0.44) NPC1MAPK8MAPK9MAPK10KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
EP-1479670-B1 NOVEL FUSED RING INDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-04-21 EP disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-7390797-B2 Fused indazole compounds EISAI CO., LTD. (JP) 2008-06-24 US disclosed
US-20060111419-A1 Novel fused indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-05-25 US disclosed
EP-1479670-A1 NOVEL FUSED RING INDAZOLE COMPOUNDS Eisai Co., Ltd. (JP) 2004-11-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111419-A1 Novel fused indazole compounds MAP2K3, MAP3K11, MAP2K2 NPC1 1991/4885RAB9A 1332/4885MAPK8 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.